ArticleCancer medicine2020

Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.

Lucia Nogova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.